Flow Partners advises Elevator Fund
Portfolio valuation and strategic review of BiomX
Tel Aviv, Israel / Branford, CT — 27 January 2021
Flow Partners acted as a financial advisor to a leading Israeli early-stage venture capital investor Elevator Fund on a portfolio valuation and strategic review of BiomX, a biotech microbiome company focused on developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectalcancer (CRC), as well as bacteria that affect the appearance of the skin.
BiomX (NYSE and TASE: PHGE) is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
About Elevator Fund
Elevator Fund invests in exceptional early-stage startups globally. Elevator leads and syndicates seed rounds, investing between $250K-$1M in innovative companies located in Israel, Europe and the US. Elevator invests in areas of fintech, new media, digital health and other emerging fields.
About Flow Partners
Flow Partners is a new-age technology advisory boutique, providing transaction advice to the companies and investors that shape up the global digital ecosystem. Founded in 2020, the firm operates worldwide and has presence in London, Berlin, Warsaw and Miami. For more information, please visit www.flowpartners.io.
For all enquiries please contact the team at firstname.lastname@example.org.